Novartis to expand oncology portfolio with acquisition of Mariana Oncology
Novartis has announced a significant move in the oncology sector with its agreement to acquire Mariana Oncology, a preclinical-stage biotechnology company based in Watertown, Massachusetts. The transaction, valued at approximately $1.75 billion, including milestone payments, underscores Novartis’s commitment to advancing its capabilities in radioligand therapies (RLTs), a promising area of cancer treatment.
Details of the Deal
Novartis will pay $1 billion upfront and an additional $750 million upon reaching pre-specified milestones. This acquisition is set to enhance Novartis’s already robust RLT pipeline and expand its research infrastructure and clinical supply capabilities, particularly in the area of solid tumor indications like breast, prostate, and lung cancer.
Impact on Novartis’s RLT Platform and Oncology Research
The acquisition includes Mariana Oncology’s portfolio of RLT programs, which range from lead optimization to early development. A highlight of these programs is the development candidate MC-339, an actinium-based RLT targeted at treating small cell lung cancer. Fiona Marshall, President of Biomedical Research at Novartis, commented on the acquisition’s potential to fortify their leadership in radioligand therapy, “We are excited to work with the Mariana team to bring forward next-generation RLTs for patients living with cancer.”
Novartis to acquire Mariana Oncology to enhance its radioligand therapy capabilities and reinforce its commitment to innovative cancer treatment solutions.
Advancing Cancer Treatment Through Precision Medicine
RLTs represent a form of precision medicine that combines tumor-targeting molecules with therapeutic radioisotopes to deliver radiation directly to the tumor, minimizing damage to surrounding healthy tissues. This targeted approach has shown promise in treating certain types of tumors with high precision and efficacy.
Future Prospects and Ongoing Innovations
With this acquisition, Novartis aims to build on its scientific leadership and expand the breadth of potentially transformative treatments. The company currently has two approved RLTs and several others in various stages of clinical development, exploring new isotopes, combinations, and disease areas.
This acquisition not only expands Novartis’s footprint in the oncology field but also sets a new precedent for the development of advanced cancer therapies, promising enhanced treatment options for patients worldwide.